Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults: A meta-analysis of randomized controlled trials
Clinical Nutrition · 2025-07 · 50 · 164-174
DOI: 10.1016/j.clnu.2025.05.013 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical Nutrition, 2025-07. Verfasst von Su Jin Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Fatty Acids, Omega-3, Dietary Supplements. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 79 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide. Previous meta-analyses investigating the effects of omega-3 polyunsaturated fatty acids (ω-3 PUFA) on NAFLD have reported inconsistent findings. This study aimed to evaluate the efficacy and adverse events (AEs) of ω-3 PUFA in adults with NAFLD. METHODS: PubMed, MEDLINE, Embase, and Cochrane Library databases were searched for randomized controlled trials (RCTs) published until November 30, 2024. Data were pooled, and meta-analyses were conducted using a random-effects model. The Cochrane Collaboration's Risk of Bias 2.0 tool was used. Subgroup analyses of aspartate aminotransferase (AST) and alanine transaminase (ALT) levels were performed based on treatment duration, dosage, metabolic dysfunction-associated steatotic liver disease (MASLD), nonalcoholic steatohepatitis (NASH), age, sex, and funding source. RESULTS: Twenty RCTs with 1615 participants were included. The overall risk of bias was 5/20 low risk (25 %), 4/20 high risk (20 %) and 11/20 some concerns (55 %). ω-3 PUFA supplementation significantly improved gamma-glutamyltransferase (GGT) (WMD = -5.38 IU/L, 95 % CI: -9.16 to -1.61) and hepatic steatosis assessed by ultrasonography (US) (OR = 3.83, 95 % CI: 1.03 to 14.27) compared with the control group, although publication bias was observed. No significant effects were observed on AST, ALT, or hepatic fat measured by magnetic resonance spectroscopy (MRS) or MRI-proton density fat fraction (MRI-PDFF), hepatic stiffness, or histology. ω-3 PUFA group was more likely to experience overall AEs compared with the control group. However, the number of RCTs reporting sufficient information was limited. CONCLUSIONS: ω-3 PUFA supplementation may improve GGT levels and hepatic steatosis assessed by US. However, substantial heterogeneity and the limited number of ultrasound-based studies necessitate further well-designed RCTs. Moreover, careful monitoring of AEs during supplementation was necessary, highlighting the need for long-term safety data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Family Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Family Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Department of Family Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Family Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Department of Family Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: ja…
Zitieren
APA
Kim, S. J., Cho, S. H., & Yun, J. M. (2025). Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults: A meta-analysis of randomized controlled trials. Clinical Nutrition, 50, 164-174. https://doi.org/10.1016/j.clnu.2025.05.013
Vancouver
Kim SJ, Cho SH, Yun JM. Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults: A meta-analysis of randomized controlled trials. Clinical Nutrition. 2025;50:164-174. doi:10.1016/j.clnu.2025.05.013
BibTeX
@article{Kim2025,
author = {Kim, Su Jin and Cho, Su Hwan and Yun, Jae Moon},
title = {Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults: A meta-analysis of randomized controlled trials},
journal = {Clinical Nutrition},
year = {2025},
volume = {50},
pages = {164--174},
doi = {10.1016/j.clnu.2025.05.013}
}
EUVIMED